Literature DB >> 18536600

Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes.

Ruth Axer-Siegel1, Idit Maharshak, Moshe Snir, Ronit Friling, Rita Ehrlich, Ilana Sherf, Benjamin Shalev, Lea Sirota, Dov Weinberger.   

Abstract

PURPOSE: To examine the anatomical and refractive outcomes of infrared diode laser photocoagulation (DLPC) for the treatment of threshold retinopathy of prematurity (ROP).
METHODS: The charts of all consecutive premature neonates with ROP treated by DLPC at our tertiary center from December 1, 1996, to December 31, 2004, were reviewed.
RESULTS: The group included 100 neonates (194 eyes) with a mean birth weight +/- SD of 833.9 +/- 250.3 g and a mean gestational age +/- SD of 26 +/- 1.9 weeks. Sixty-two percent of neonates had zone I or posterior zone II ROP. Each eye received a mean +/- SD of 1,740 +/- 990 laser applications, and 21% of eyes received an additional 1 to 2 rows posterior to the ridge. Neonates treated after December 2003 (cutoff date of the Early Treatment of Retinopathy of Prematurity study) underwent a significantly greater number of laser applications (mean +/- SD, 2,286 +/- 1,087) than did neonates treated earlier. Anatomical results of laser treatment were favorable for 179 eyes (92.3%) at a mean follow-up +/- SD of 33.6 +/- 27.2 months. After vitreoretinal surgery, partial or total retinal detachment was documented for 2.5% of patients who received posterior-to-the-ridge laser treatment and 3.8% of patients treated only on the avascular retina. Refractive data were available for 134 eyes: 55.2% had myopia of -5 diopters (31.3%) or greater (23.9%). Strabismus was found in 21 (28.8%) of 73 neonates tested. Gestational age was correlated with corrected age at treatment, zone of ROP, number of laser applications, and spherical equivalent. Snellen visual acuity of 6/12 or more occurred in 17 of 24 patients who complied with testing.
CONCLUSION: DLPC is a safe and effective treatment for ROP. Neonates of lower gestational age and birth weight require earlier and more aggressive laser treatment and may have a higher refractive error.

Entities:  

Mesh:

Year:  2008        PMID: 18536600     DOI: 10.1097/IAE.0b013e318169faee

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  21 in total

1.  One-year clinical outcome after laser treatment for retinopathy of prematurity at a tertiary center in Turkey.

Authors:  Murat Gunay; Gokhan Celik; Fahri Ovali; Huseyin Yetik; Alev Aktas; Betul Onal Gunay
Journal:  Int Ophthalmol       Date:  2014-11-09       Impact factor: 2.031

2.  Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.

Authors:  Venkateshnaidu Laveti; Divya Balakrishnan; Padmaja Kumari Rani; Ashik Mohamed; Subhadra Jalali
Journal:  Int Ophthalmol       Date:  2020-08-10       Impact factor: 2.031

3.  Outcome of solid-state 532 nm green laser in high-risk retinopathy of prematurity at a tertiary care centre in India.

Authors:  Kanika Chhabra; Prempal Kaur; Karamjit Singh; Anand Aggarwal; Dharamvir Chalia
Journal:  Int Ophthalmol       Date:  2017-02-15       Impact factor: 2.031

4.  Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study.

Authors:  Yu-Bai Chou; An-Guor Wang; Hsin-Yu Yang; Kuan-Jung Chen; Chang-Sue Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-22       Impact factor: 3.117

5.  Posterior to the ridge laser treatment for severe stage 3 retinopathy of prematurity.

Authors:  A L Ells; G A Gole; P Lloyd Hildebrand; A Ingram; C M Wilson; R Geoff Williams
Journal:  Eye (Lond)       Date:  2013-01-18       Impact factor: 3.775

6.  Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: a case report.

Authors:  Hae Jung Sun; Kyung Seek Choi; Sung Jin Lee
Journal:  Jpn J Ophthalmol       Date:  2012-07-28       Impact factor: 2.447

7.  Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes.

Authors:  Y-H Chen; S-N Chen; R-I Lien; C-P Shih; A-N Chao; K-J Chen; Y-S Hwang; N-K Wang; Y-P Chen; K-H Lee; C-C Chuang; T-L Chen; C-C Lai; W-C Wu
Journal:  Eye (Lond)       Date:  2014-08-08       Impact factor: 3.775

Review 8.  The progress of prophylactic treatment in retinopathy of prematurity.

Authors:  Hong-Bing Zhang; Xiao-Dong Wang; Kun Xu; Xiao-Gang Li
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

9.  Structural sequelae and refractive outcome 1 year after laser treatment for type 1 prethreshold retinopathy of prematurity in Asian Indian eyes.

Authors:  Deeksha Katoch; Gaurav Sanghi; Mangat R Dogra; Nikhil Beke; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2011 Nov-Dec       Impact factor: 1.848

10.  Structural and functional results of indirect diode laser treatment for retinopathy of prematurity from 1999 to 2003 in Kuwait.

Authors:  Vivek B Wani; Khalid Al Sabti; Niranjan Kumar; Seemant Raizada; Jamal Al Kandari; Mohammad Al Harbi; Rima Sawaan; Usha Rajaram; Niran Al-Naqeeb; Mumtaz Shukkur
Journal:  Clin Ophthalmol       Date:  2013-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.